Oncorena AB
- Biotech or pharma, therapeutic R&D
Oncorena is a clinical phase pharmaceutical company developing a highly organ-specific, targeted, cytotoxic anti-cancer treatment, ONC175, for patients with metastatic renal cell carcinoma. The clinical phase 1-2 trial, Oncorella-1, is conducted in the rare population of patients with metastatic renal cell carcinoma (mRCC) and hemodialysis (HD) having the highest benefit/risk-ratio. If successful, the patient population likely will be expanded to all patients with mRCC not responding to 1st line therapy. The adaptive study design has three parts. Part A was conducted at Karolinska, Stockholm as an in-patient, dose escalation study. After reviewing early safety and efficacy signals, FDA approved the IND 167761 in March 2025 opening Part B - Dose Exposure at several sites in the US and in Europe. Part C is the dose expansion phase 2 component of the trial that potentially can suffice for accelerated (conditional) approval.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}